SCHEDULE 13G: Dodge & Cox Discloses 5.6% Passive Stake in Neurocrine Biosciences
Beneficial Ownership Report
Investment adviser Dodge & Cox has filed a Schedule 13G, revealing a 5.6% beneficial ownership stake in Neurocrine Biosciences, Inc. as of March 31, 2025.
Summary
- Dodge & Cox, an investment adviser based in San Francisco, California, has reported beneficial ownership of 5,534,624 shares of Neurocrine Biosciences, Inc. common stock.
- This ownership represents 5.6% of the total outstanding shares of Neurocrine Biosciences, Inc.
- The filing indicates that Dodge & Cox holds sole voting power over 5,268,075 shares and sole dispositive power over all 5,534,624 shares.
- The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of the issuer.
- The clients of Dodge & Cox, including registered investment companies and other managed accounts, retain the right to receive dividends and proceeds from the sale of these securities.
Sentiment
Score: 6
Explanation: The document is a factual disclosure of a significant passive ownership stake by a reputable investment firm. While not directly commenting on company performance, a substantial institutional investment can be perceived as a positive signal of confidence in the issuer's long-term prospects.
Positives
- The disclosure of a significant stake by a reputable investment adviser like Dodge & Cox may be viewed as a vote of confidence in Neurocrine Biosciences by a major institutional investor.
Negatives
- This document, a Schedule 13G, is a passive ownership disclosure and does not contain information typically categorized as 'negatives' regarding the issuer's performance or operations.
Risks
- This document is an ownership disclosure and does not detail specific risks related to Neurocrine Biosciences, Inc.'s operations or financial health.
Future Outlook
This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance regarding Neurocrine Biosciences, Inc.'s future performance or strategic outlook.
Industry Context
This filing indicates a significant institutional investment in Neurocrine Biosciences, a company operating in the biotechnology and pharmaceutical sector. While the filing itself does not provide industry-specific analysis, the investment by Dodge & Cox reflects their portfolio allocation decisions within the broader healthcare and life sciences industry.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake by Dodge & Cox provides transparency regarding the company's ownership structure and may influence investor sentiment and trading activity.
- Company Management: Awareness of a major institutional investor's stake can influence management's strategic decisions and communication with the investment community.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires the filing of this statement, indicating the beneficial ownership position as of this date. |
| 05/14/2025 | Date the Schedule 13G statement was signed and filed by Dodge & Cox. |
Keywords
Neurocrine Biosciences, Dodge & Cox, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Institutional Investor, Biotechnology, Pharmaceuticals, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.